Guidant's CTS Buy Provides Platform For Growth In Cardiac Surgery Market
This article was originally published in The Gray Sheet
Executive Summary
Guidant's planned acquisition of minimally invasive cardiac surgery device maker CardioThoracic Systems for $313 mil. in stock provides greater access to cardiac surgeons as well as a platform for growth in the cardiac surgery market.
You may also be interested in...
J&J/Ethicon Bets On Minimally Invasive CABG With $81 Mil. Heartport Buy
Johnson & Johnson's Ethicon subsidiary signaled its confidence in the future of minimally invasive coronary artery bypass grafting (CABG) with its Jan. 26 agreement to buy Heartport, Inc. for $81 mil.
J&J/Ethicon Bets On Minimally Invasive CABG With $81 Mil. Heartport Buy
Johnson & Johnson's Ethicon subsidiary signaled its confidence in the future of minimally invasive coronary artery bypass grafting (CABG) with its Jan. 26 agreement to buy Heartport, Inc. for $81 mil.
Jomed To Begin Anastomosis Device Clinicals In Second Quarter 2000
Swedish-based stent manufacturer Jomed is looking to start European clinical studies for a sutureless graft connector anastomosis system by the second quarter of 2000, the company said, in the wake of promising six-month animal data.